US Patent Issued to IHG Pharmaco on Dec. 9 for "Carrier status of annexin A5 M2 haplotype and obstetric risks" (British Inventor)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,491,206, issued on Dec. 9, was assigned to IHG Pharmaco Ltd. (London).

"Carrier status of annexin A5 M2 haplotype and obstetric risks" was invented by Deborah Jane Baker (Warwick, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to determining the carrier status of Annexin A5 M2 haplotype of parents (both male and female) prior to and/or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (RPL), infertility, miscarriage, in vitro fertilization (IVF) failure, IUI failure, implantation failure, foetal growth restriction (FGR), small for gestationa...